# US 2008/0307534 A1 · Methods and Compositions for the Detection and Isolation of Ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0307534 A1
- Document ID: US20080307534A1
- Status: Published application
- Kind: A1
- Application number: 12/158,383
- Filed: 2006-12-22
- Published: 2008-12-11
- Earliest claimed: 2005-12-22
- Assignees: InDanio Bioscience Inc.
- Inventors: Henry M. Krause; Jens Tiefenbach
- Web page: https://patentgrep.com/patent/US20080307534A1

## CPC

- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- C12Q 1/6897: involving reporter genes operably linked to promoters
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/715: containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for the detection and isolation of ligands, preferably nuclear receptor ligands, bound to their cognate receptors in live animals, is described. A novel composition comprising 1) a chimeric transcription factor containing a DNA-binding domain, preferably from a non-vertebrate transcription factor, fused to the ligand-binding domain (LBD) of a nuclear receptor, 2) a reporter system, driven by a promoter that contains binding sites for the chosen DNA-binding domain, 3) multiple affinity tags fused to the LBD fusion proteins to facilitate efficient purification, along with specifically associated molecules and 4) sequences required for simultaneous genomic integration of all three components above are described. To make use of the system, expression of the chimeric LBD protein is broadly induced.

## Claims

### Claim 1

A composition comprising
(a) a first nucleic acid encoding a fusion protein of a DNA-binding domain, a ligand-binding domain and multiple affinity tags; and
(b) a second nucleic acid encoding a reporter system, said second nucleic acid comprising a promoter having binding sites for the DNA-binding domain and encoding a reporter protein.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the DNA-binding domain is Gal4.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the ligand-binding domain is derived from a Nuclear Receptor protein.

### Claim 4 (depends on 1)

The composition of claim 1, wherein there are at least three different affinity tags.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the at least three different affinity tags are StrepII, His and FLAG.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the first nucleic acid further comprises an inducible promoter.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the inducible promoter is heat, transcription factor or hormone activated.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the inducible promoter is hsp70.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the reporter protein is selected from the group consisting of green fluorescent protein, red fluorescent protein, DS-red and luciferase.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the reporter protein is enhanced green fluorescent protein.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the first and second nucleic acids are on a single vector.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the single vector comprises the nucleotide sequence as shown in SEQ ID NO:1.

### Claim 13 (depends on 1)

A use of the composition of claim 1 for in vivo ligand detection.

### Claim 14 (depends on 1)

An in vivo method for detecting an endogenous ligand comprising
(a) providing an animal, said animal having the first and second nucleic acids of the composition of claim 1 transiently expressed or incorporated into its genome;
(b) inducing expression of the first nucleic acid; and
(c) detecting a change, if any, in expression of the reporter protein;
wherein the change in expression indicates that at least one endogenous ligand is present.

### Claim 15 (depends on 1)

An in vivo method for screening a test compound for its ability to interact with a ligand-binding domain, said method comprising
(a) providing an animal, said animal having the first and second nucleic acids of the composition of claim 1 transiently expressed or incorporated into its genome;
(b) contacting the transgenic animal with the test compound;
(c) inducing expression of the first nucleic acid;
(d) detecting a change, if any, in expression of the reporter protein, wherein the change indicates that the test compound interacts with the ligand-binding domain.

### Claim 16 (depends on 14)

The method of claim 14, wherein the animal is selected from the group consisting of C. elegans, Drosophila, Xenopus, mouse and zebrafish.

### Claim 17 (depends on 14)

The method of claim 14, wherein the animal is zebrafish.

### Claim 18 (depends on 1)

A method for purifying a modulator of a reporter system, the method comprising:
(a) providing an animal, said animal having the first and second nucleic acids of the composition of claim 1 transiently expressed or incorporated into its genome;
(b) inducing expression of the first nucleic acid;
(c) detecting a signal;
(d) generating a cellular extract from the animal; and
(e) subjecting the cellular extract generated in step (d) to multiple affinity purification steps, each step comprising binding one affinity tag to an affinity resin capable of selectively binding one affinity tag and eluting the affinity tag from the affinity resin after substances not bound to the fusion protein have been removed.

### Claim 19 (depends on 18)

The method of claim 18, further comprising subjecting the purified substance of step (e) to MALDI-TOV, ESI, GC or semi non-denaturing mass spectrometry.

### Claim 20 (depends on 1)

A method for purifying a modulator of a reporter system, the method comprising the steps of:
(a) providing an animal, said animal having the first and second nucleic acids of the composition of claim 1 transiently expressed or incorporated into its genome;
(b) contacting the animal with a test compound;
(c) turning on the first promoter;
(d) detecting a signal;
(e) generating a cellular extract from the animal; and
(f) subjecting the cellular extract generated in step (e) to multiple different affinity purification steps, each step comprising binding one affinity tag to an affinity resin capable of selectively binding one affinity tag and eluting the affinity tag from the affinity resin after substances not bound to the fusion protein have been removed.

### Claim 21 (depends on 20)

The method of claim 20, further comprising subjecting the purified substance of step (e) to MALDI-TOV, ESI, GC or semi non-denaturing mass spectrometry.
